Recent years have witnessed remarkable advances in the diagnosis and treatment of upper gastrointestinal cancers. Innovations in endoscopic techniques, imaging modalities, and multidisciplinary treatment approaches have steadily contributed to improved patient outcomes. In particular, the rapid evolution of pharmacotherapy — including molecular targeted agents, immune checkpoint inhibitors, and antibody-drug conjugates (ADCs) — has fundamentally transformed the treatment landscape for both esophageal and gastric cancers, offering new hope to patients with advanced or refractory disease. Despite these encouraging developments, significant challenges remain. Issues such as treatment resistance, patient selection for optimal therapy, and the management of treatment-related adverse events continue to demand attention from clinicians and researchers alike. Furthermore, the identification of reliable predictive biomarkers and the integration of novel therapeutic combinations into standard clinical practice remain areas of active investigation worldwide. In this seminar, we are honored to welcome Dr. Kei Muro from Aichi Cancer Center, a nationally and internationally acclaimed expert in the pharmacotherapy for gastrointestinal malignancies, including esophageal and gastric cancers. Drawing on his extensive clinical and research experience — including his leadership in numerous pivotal clinical trials — Dr. Muro will deliver a comprehensive lecture covering both esophageal and gastric cancers. His presentation will range from practical approaches in daily clinical practice to the latest evidence-based treatment strategies, providing attendees with valuable insights that can be directly applied to patient care. This session is intended for medical oncologists, gastrointestinal surgeons, endoscopists, and all healthcare professionals involved in the management of upper gastrointestinal malignancies. We anticipate that this seminar will foster meaningful discussion and inspire further advances in the field.